VECTIBIX (panitumumab)
ANTINEOPLASTIC - EGFR INHIBITORS, MONOCLONAL ANTIBODIES · WILD-TYPE KRAS AND NRAS COLORECTAL CANCER ·+1
AMGEN
Drug class
Antineoplastic - EGFR Inhibitors, Monoclonal Antibodies
Antineoplastic EGFR-inhibiting monoclonal antibodies are a targeted class of biologics that bind specifically to the extracellular ligand-binding domain of the epidermal growth factor receptor (EGFR). Read more about Antineoplastic - EGFR Inhibitors, Monoclonal Antibodies
2 drugs in this class 2 manufacturers
Drugs in Antineoplastic - EGFR Inhibitors, Monoclonal Antibodies
ERBITUX (cetuximab)
ANTINEOPLASTIC - EGFR INHIBITORS, MONOCLONAL ANTIBODIES · SQUAMOUS CELL CARCINOMA OF HEAD AND NECK ·+2
Eli Lilly and Company
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - EGFR Inhibitors, Monoclonal Antibodies preselected. Add indication or manufacturer filters there.
Antineoplastic EGFR-inhibiting monoclonal antibodies are a targeted class of biologics that bind specifically to the extracellular ligand-binding domain of the epidermal growth factor receptor (EGFR).
By sterically blocking endogenous ligands such as EGF and TGF-alpha, these agents inhibit receptor dimerization, suppress downstream intracellular signaling pathways that drive cellular proliferation and survival, and may recruit immune-mediated cytotoxic responses.
Representative therapies in this subclass—including cetuximab, panitumumab, and necitumumab—are primarily indicated for the treatment of wild-type RAS metastatic colorectal cancer, locally advanced or recurrent head and neck squamous cell carcinoma, and select cases of non-small cell lung cancer.
-
fda.gov
Antineoplastic EGFR-inhibiting monoclonal antibodies are a targeted class of biologics that bind specifically to the extracellular ligand-binding domain of the epidermal growth factor receptor (EGFR) By sterically blocking endogenous ligands such as EGF and TGF-alpha, these agents inhibit receptor dimerization, suppress downstream intracellular signaling pathways that drive cellular proliferation and survival, and may recruit immune-mediated cytotoxic responses Representative therapies in this s...
-
rxlist.com
Antineoplastic EGFR-inhibiting monoclonal antibodies are a targeted class of biologics that bind specifically to the extracellular ligand-binding domain of the epidermal growth factor receptor (EGFR)
-
nih.gov
By sterically blocking endogenous ligands such as EGF and TGF-alpha, these agents inhibit receptor dimerization, suppress downstream intracellular signaling pathways that drive cellular proliferation and survival, and may recruit immune-mediated cytotoxic responses Representative therapies in this subclass—including cetuximab, panitumumab, and necitumumab—are primarily indicated for the treatment of wild-type RAS metastatic colorectal cancer, locally advanced or recurrent head and neck squamous ...
-
nih.gov
Representative therapies in this subclass—including cetuximab, panitumumab, and necitumumab—are primarily indicated for the treatment of wild-type RAS metastatic colorectal cancer, locally advanced or recurrent head and neck squamous cell carcinoma, and select cases of non-small cell lung cancer
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.